430 results on '"Yu, Paul B."'
Search Results
2. Angiogenesis Redux: An Overall Protective Role of VEGF/KDR Signaling in the Microvasculature in Pulmonary Arterial Hypertension
3. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
4. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension
5. Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography
6. NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension
7. Abstract 13237: Single Cell Transcriptomes Reveal Novel Macrophage and Endothelial Subtypes in Pulmonary Hypertension
8. Abstract 10998: Pulmonary Artery Pulsatility Measured by Cardiac Magnetic Resonance Imaging in Over 42,000 Participants Reveals Novel Genetic Risk Loci
9. The role of bone morphogenetic protein signaling in vascular calcification
10. Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis
11. Targeting BMP signalling in cardiovascular disease and anaemia
12. Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases
13. Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells
14. Brief Report
15. Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva
16. A New Link in the Chain: Unspliced XBP1 in Wnt Signaling and Vascular Calcification
17. Anti-ACVRI antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressive (FOP) by activating FOP-mutant ACVR1
18. FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis--Brief Report.
19. Intrapulmonary arterial contraction assay reveals region-specific deregulation of vasoreactivity to lung injuries
20. Bone Morphogenetic Protein Signaling in Pulmonary Arterial Hypertension
21. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva
22. Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis
23. WNT7A deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension
24. Abstract 14787: Loss of Wnt7a is Associated With Reduced Vegf-a/vegfr2 Mediated Endothelial Tip Cell Formation and Angiogenesis in Pulmonary Arterial Hypertension
25. Periostin: A Novel Integrator of Hypoxic Signaling in Pulmonary Hypertension
26. Animal Models of Pulmonary Hypertension
27. The traumatic bone: trauma-induced heterotopic ossification
28. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation
29. Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice
30. Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification
31. Angiogenesis Redux: An Overall Protective Role of VEGF/KDR Signaling in the Microvasculature in Pulmonary Arterial Hypertension.
32. Pharmacologic Strategies for Assaying BMP Signaling Function
33. Letter by Morrell et al Regarding Article, “Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension”
34. In Search of the Second Hit in Pulmonary Arterial Hypertension
35. Hepatopulmonary Syndrome, Another Face of Dysregulated BMP9 Signaling.
36. Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension
37. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6
38. Room With a View: Towards Molecular Imaging of Pulmonary Vascular Remodeling
39. Abstract 18906: ACTRIIA-Fc Rebalances BMP and Activin/TGF-β Signaling to Attenuate Experimental Pulmonary Hypertension
40. Abstract 17828: 89Zr-Bevacizumab PET Detects Arteriolar Remodeling In Experimental Pulmonary Hypertension
41. Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth
42. Contributions of Muscle-Resident Progenitor Cells to Homeostasis and Disease
43. Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart
44. The Origin of Xenoreactive Natural Antibodies
45. Specificity of Xenoreactive Natural Antibodies
46. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension
47. Additional file 1 of Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
48. Additional file 2 of Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
49. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
50. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.